Evidence map›Paper›PMID 38493138›Full record

SynthesisBMC infectious diseases2024

Association of interleukin-6, ferritin, and lactate dehydrogenase with venous thromboembolism in COVID-19: a systematic review and meta-analysis.

Haiyu Liu, Ningjing Guo, Qixian Zheng, Qianyuan Zhang, Jinghan Chen, Yuanyuan Cai, Qiong Luo, Qian Xu, Xiangqi Chen, Sheng Yang and 1 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Dynamic Prediction of Venous Thromboembolism in Gynecological Surgery Using Perioperative Biomarkers and an Extremely Randomized Trees Model: A Retrospective Case-Control Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Haiyu LiuDepartment of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China.
Ningjing Guo *Department of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China.
Qixian Zheng *Department of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China.
Qianyuan ZhangDepartment of General Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China.
Jinghan ChenDepartment of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China.
Yuanyuan CaiDepartment of General Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China.
Qiong LuoDepartment of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China.
Qian XuDepartment of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China.
Xiangqi ChenDepartment of Pulmonary and Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China. drchxqtg@126.com.
Sheng YangDepartment of Oncology Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China. dryangxh2017@sina.com.
Suyun ZhangDepartment of Internal Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, P.R. China. fjhyhlczlfhwcxz@126.com.
Fujian Medical University · CNUnion Hospital · CN

Funding

Fujian Provincial Health Technology Project Project No. 2021Y0098
6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19) is frequntly accompanied by venous thromboembolism (VTE), and its mechanism may be related to the abnormal inflammation and immune status of COVID-19 patients. It has been proved that interleukin-6 (IL-6), ferritin and lactate dehydrogenase (LDH) may play an important role in the occurrence of VTE in COVID-19 infection. But whether they can server as predictors for VTE in COVID-19 is still unclear. In this study, we performed a systematic review and meta-analysis to compare IL-6, ferritin and LDH in VTE and non-VTE COVID-19 patients in order to shed light on the prevention and treatment of VTE.

methodsRelated literatures were searched in PubMed, Embase, Web of Science, Google Scholar, China National Knowledge Infrastructure (CNKI), WANGFANG. COVID-19 patients were divided into VTE group and non-VTE group. Meta-analysis was then conducted to compare levels of IL-6, ferritin and LDH between the two groups.

resultsWe finally included and analyzed 17 literatures from January 2019 to October 2022. There was a total of 7,035 COVID-19 patients, with a weighted mean age of 60.01 years. Males accounted for 62.64% and 61.34% patients were in intensive care unit (ICU). Weighted mean difference (WMD) of IL-6, ferritin and LDH was 31.15 (95% CI: 9.82, 52.49), 257.02 (95% CI: 51.70, 462.33) and 41.79 (95% CI: -19.38, 102.96), respectively. The above results indicated that than compared with non-VTE group, VTE group had significantly higher levels of IL-6 and ferritin but similar LDH.

conclusionThis systematic review and meta-analysis pointed out that elevated levels of IL-6 and ferritin were significantly possitive associated with VTE, thus could be used as biological predictive indicators of VTE among COVID-19 patients. However, no association was found between level of LDH and VTE. Therefore, close monitoring of changes in IL-6 and ferritin concentrations is of great value in assisting clinicans to rapidly identify thrombotic complications among COVID-19 patients, hence facilitating the timely effective managment. Further studies are required in terms of the clinical role of cytokines in the occurrence of VTE among COVID-19 infection, with more reliable systematic controls and interventional trials.

Indexed as

COVID-19Venous ThromboembolismFerritinsHumansInterleukin-6L-Lactate DehydrogenaseMaleMiddle AgedFerritinsInterleukin-6L-Lactate DehydrogenaseCOVID-19Cytokine stormFerritinIL-6LDHThrombosis prevention and anticoagulation therapyVTE

Identifiers

PMID38493138
PMCPMC10943892
OpenAlexW4392880047

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.